stoxline Quote Chart Rank Option Currency Glossary
  
Acrivon Therapeutics, Inc. Common Stock (ACRV)
7.17  0.2 (2.87%)    02-06 11:26
Open: 6.77
High: 7.24
Volume: 25,085
  
Pre. Close: 6.97
Low: 6.53
Market Cap: 223(M)
Technical analysis
2025-02-06 10:46:03 AM
Short term     
Mid term     
Targets 6-month :  9.34 1-year :  10.91
Resists First :  8 Second :  9.34
Pivot price 5.84
Supports First :  6.31 Second :  5.28
MAs MA(5) :  6.3 MA(20) :  5.79
MA(100) :  6.96 MA(250) :  7.16
MACD MACD :  0 Signal :  -0.2
%K %D K(14,3) :  62.7 D(3) :  57
RSI RSI(14): 63.2
52-week High :  11.89 Low :  3.19
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ ACRV ] has closed Bollinger Bands are 5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 8.01 - 8.04 8.04 - 8.06
Low: 5.77 - 5.8 5.8 - 5.82
Close: 6.92 - 6.97 6.97 - 7.01
Company Description

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.

Headline News

Wed, 05 Feb 2025
The -10.05% Simple Moving Average of Acrivon Therapeutics Inc’s (ACRV) Stock in the Past 200 Days - The News Heater

Sat, 01 Feb 2025
JPMorgan Chase & Co. Has $238,000 Position in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World

Sun, 19 Jan 2025
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Sees Significant Growth in Short Interest - MarketBeat

Thu, 12 Dec 2024
Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis - Seeking Alpha

Wed, 13 Nov 2024
Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewswire

Wed, 13 Nov 2024
Acrivon's Cancer Drug Shows 62.5% Response Rate; Reports $202.8M Cash Position - StockTitan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 31 (M)
Shares Float 11 (M)
Held by Insiders 22.3 (%)
Held by Institutions 75.9 (%)
Shares Short 1,080 (K)
Shares Short P.Month 1,210 (K)
Stock Financials
EPS -2.67
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 5.38
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -24.5 %
Return on Equity (ttm) -37.8 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.43
Qtrly Earnings Growth 0 %
Operating Cash Flow -53 (M)
Levered Free Cash Flow -31 (M)
Stock Valuations
PE Ratio -2.63
PEG Ratio 0
Price to Book value 1.29
Price to Sales 0
Price to Cash Flow -4.1
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android